SEARCH

SEARCH BY CITATION

References

  • Barnes K, McIntosh E, Whetton AD, Daley GQ, Bentley J, Baldwin SA (2005). Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation. Oncogene 24: 32573267.
  • Boren J, Cascante M, Marin S, Comin-Anduix B, Centelles JJ, Lim S et al. (2001). Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells. J Biol Chem 276: 3774737753.
  • Boros LG, Cascante M, Lee WN (2002). Metabolic profiling of cell growth and death in cancer: applications in drug discovery. Drug Discov Today 7: 364372.
  • Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ et al. (1996). Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56: 100104.
  • Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ et al. (2000). Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295: 139145.
  • le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, Cabrita G et al. (2000). Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 95: 17581766.
  • Deininger MW, Goldman JM, Lydon N, Melo JV (1997). The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 90: 36913698.
  • Deininger MW, Goldman JM, Melo JV (2000). The molecular biology of chronic myeloid leukemia. Blood 96: 33433356.
  • Desplat V, Belloc F, Lagarde V, Boyer C, Melo JV, Reiffers J et al. (2005). Overproduction of BCR-ABL induced apoptosis in imatinib-mesylate resistant cell lines. Cancer 103: 102110.
  • Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R et al. (2003). BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101: 690698.
  • Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. (1996). Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2: 561566.
  • Evelhoch JL, Gillies RJ, Karczmar GS, Koutcher JA, Maxwell RJ, Nalcioglu O et al. (2000). Applications of magnetic resonance in model systems: cancer therapeutics. Neoplasia 2: 152165.
  • Franks SE, Smith MR, Arias-Mendoza F, Shaller C, Padavic-Shaller K, Kappler F et al. (2002). Phosphomonoester concentrations differ between chronic lymphocytic leukemia cells and normal human lymphocytes. Leuk Res 26: 919926.
  • Gambacorti-Passerini C, le Coutre P, Mologni L, Fanelli M, Bertazzoli C, Marchesi E et al. (1997). Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis 23: 380394.
  • Glunde K, Serkova NJ (2006). Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism. Pharmacogenomics 7: 11091123.
  • Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. (2001). Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876880.
  • Gottschalk S, Anderson N, Hainz C, Eckhardt SG, Serkova NJ (2004). Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells. Clin Cancer Res 10: 66616668.
  • Grimpen F, Yip D, McArthur G, Waring P, Goldstein D, Loughrey M et al. (2005). Resistance to imatinib, low-grade FDG-avidity on PET, and acquired KIT exon 17 mutation in gastrointestinal stromal tumour. Lancet Oncol 6: 724727.
  • Henke J, Engelmann J, Kutscher B, Nessner G, Engel J, Voegeli R et al. (1999). Changes of intracellular calcium, fatty acids and phospholipids during miltefosine-induced apoptosis monitored by fluorescence- and 13C NMR-spectroscopy. Anticancer Res 19: 40274032.
  • Jordanides NE, Jorgensen HG, Holyoake TL, Mountford JC (2006). Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood 108: 13701373.
  • Kaplan O, van Zijl PC, Cohen JS (1990). Information from combined 1H and 31P NMR studies of cell extracts: differences in metabolism between drug-sensitive and drug-resistant MCF-7 human breast cancer cells. Biochem Biophys Res Commun 169: 383390.
  • Kim JH, Chu SC, Gramlich JL, Pride YB, Babendreier E, Chauhan D et al. (2005). Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood 105: 17171723.
  • Klawitter J, Schmitz V, Klawitter J, Leibfritz D, Christians U (2007). Development and validation of an assay for the quantification of 11 nucleotides using LC/LC-electrospray ionization-MS. Anal Biochem 365: 230239.
  • Klawitter J, Zhang YL, Klawitter J, Anderson N, Serkova NJ, Christians U (2009). Development and validation of a sensitive assay for the quantification of imatinib mesylate using LC/LC-MS/MS in blood and cell culture. J Chromatogr B Biomed Sci Appe (in press).
  • Lyon RC, Cohen JS, Faustino PJ, Megnin F, Myers CE (1988). Glucose metabolism in drug-sensitive and drug-resistant human breast cancer cells monitored by magnetic resonance spectroscopy. Cancer Res 48: 870877.
  • Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM et al. (2000). Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96: 10701079.
  • Melo JV, Chuah C (2007). Resistance to imatinib mesylate in chronic myeloid leukaemia. Cancer Lett 249: 121132.
  • Morse DL, Carroll D, Day S, Gray H, Sadarangani P, Murthi S et al. (2009). Characterization of breast cancers and therapy response by MRS and quantitative gene expression profiling in the choline pathway. NMR Biomed 22: 114127.
  • Plas DR, Thompson CB (2005). Akt-dependent transformation: there is more to growth than just surviving. Oncogene 24: 74357442.
  • Robey IF, Stephen RM, Brown KS, Baggett BK, Gatenby RA, Gillies RJ (2008). Regulation of the Warburg effect in early-passage breast cancer cells. Neoplasia 10: 745756.
  • Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Lai JL, Philippe N, Facon T et al. (2002). Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100: 10141018.
  • Serkova N, Boros LG (2005). Detection of resistance to imatinib by metabolic profiling: clinical and drug development implications. Am J Pharmacogenomics 5: 293302.
  • Serkova N, Fuller TF, Klawitter J, Freise CE, Niemann CU (2005). 1H-NMR based metabolic signatures of mild and severe ischemia/reperfusion injury in rat kidney transplants. Kidney Int 67: 11421151.
  • Thomas J, Wang L, Clark RE, Pirmohamed M (2004). Active transport of imatinib into and out of cells: implications for drug resistance. Blood 104: 37393745.
  • Van Etten RA (2004). Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era. Leuk Res 28: S21S28.
  • Warburg O (1956). On the origin of cancer cells. Science 123: 309314.
  • Wu J, Meng F, Lu H, Kong L, Bornmann W, Peng Z et al. (2008). Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells. Blood 111: 38213829.
  • Zamaraeva MV, Sabirov RZ, Maeno E, Ando-Akatsuka Y, Bessonova SV, Okada Y (2005). Cells die with increased cytosolic ATP during apoptosis: a bioluminescence study with intracellular luciferase. Cell Death Differ 12: 13901397.
  • Zhou R, Vander Heiden MG, Rudin CM (2002). Genotoxic exposure is associated with alterations in glucose uptake and metabolism. Cancer Res 62: 35153520.
  • Zwingmann C, Leibfritz D (2003). Regulation of glial metabolism studied by 13C-NMR. NMR Biomed 16: 370399.